Currently there is no plan for a public inquiry into the prescribing of diethylstilbestrol (DES). A public inquiry to investigate any current safety concerns regarding DES would be a matter for the Medicines and Healthcare products Regulatory Agency (MHRA) as the UK independent medicines regulator.